(Date:12/2/2009)... SINGAPORE, Dec. 2 S*BIO Pte Ltd t...l JAK2 inhibitor, SB1518, at The American Society ...n New Orleans. ,, Data will be presented on the... trial of SB1518 detailing its safety, tolerabilit...ile in dose levels ranging from 100 to 600 mg. The...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world ...in turmoil and uncertainty is part of many,busines...ndustry has been,relatively immune to the economic.... , During the midst of the difficult tim...p; Johnson inaugurated an R&D center in Shangh...
(Date:12/1/2009)...E VILLAGE, Nev., Dec. 1 ...nnounced revenue guidance for the fourth quarter e...n, as compared with $69 million for the fourth qua...lts was the first of two installment payments of $...h quarter 2008 results was a one-time $1.8 million...
(Date:12/1/2009)...UTH, Mass., Dec. 1 Harvest Technol...y results from the company sponsored 60-patient cl...Center in Chennai, India using the company,s BMAC ...Critical Limb Ischemia (CLI). Sri Ramachandra Medi...ciated institution based in Chennai, India and one...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3...hat up to 30% of coffees ordered as "decaf&qu...now for sure with D+CAF, the first do-it-yourself ... leader in at-home water quality testing ( www.caf...ia, CA (PRWEB) November 12, 2008 -- Ever wonder wh...ecaf? Now you can know for sure with new D+CAF, t...
...E:,GSK) announced today that Gemstone Acquisition ...commencing a cash tender offer to purchase all,out...logies, Inc. (Nasdaq:,GNLB), for $1.30 in cash wit...xes. The tender offer is being made pursuant to a ...dated October 29, 2008 among Genelabs,Gemstone and...
...:,ADL), a vertically integrated pharmaceutical com...d today preliminary third quarter earnings and,rev...arter of FY2008, AMDL expects gross sales to be,ap...s promotions of,approximately $9.2 million. Gross ...n and income from operations to be approximately $...
Other Biology Technology:Is Your Decaf Really Decaf? Use New "D+CAF (tm) Caffeine Test Strips" to Know for Sure 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 2GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc. 3AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 3...pathic effect inhibition assays, also known as CPE...ue culture supernatents; serum from PK studies and... is defined as the quantity of interferon required... viral infection by 50%. All standards used in o...
Topoisomerase I from Invitrogen
... type I eukaryotic topoisomerase that removes both...lled right- and left-handed supercoils) from coval... covalently closed, circular DNA with fewer positi...se I does not absolutely require Mg 2+ to functio...
Eco RII (Bst NI) from Roche Applied Science
Biology Products: